---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-278533"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2026-06-23T12:00:06+00:00"
generated_at: "2026-06-23T12:05:55.247395+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phathom completes enrollment in Phase 2 EoE trial; topline data expected Q4 2026

## Summary
- Enrolled 95 adults at 41 US sites in pHalcon-EoE-201 Phase 2 trial of VOQUEZNA for eosinophilic esophagitis.
- Patients randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks; optional open-label extension.
- Topline results anticipated in Q4 2026; positive data could lead to FDA discussions on pediatric exclusivity.

## SEC filing metadata
- accession: 0001193125-26-278533
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2026-06-23T12:00:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/0001193125-26-278533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-278533
- JSON: https://secwatch.observer/filing/0001193125-26-278533.json
- Plain text: https://secwatch.observer/filing/0001193125-26-278533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.